Lupus Anticoagulant Test

Your body might be producing antibodies right now that dramatically increase your risk of blood clots, stroke, and pregnancy loss, and no routine blood test will catch it. Lupus anticoagulant (LA) is one of the strongest predictors of abnormal clotting in all of medicine, yet most people have never heard of it and most standard lab panels do not include it.

The name itself is misleading on two counts. You do not need lupus to have it, and it does not prevent clotting. LA was first discovered in two patients with systemic lupus erythematosus over 50 years ago, but it occurs in many conditions and even in apparently healthy people. And while it slows down clotting in a test tube, it does the opposite inside your body: it promotes clot formation. Understanding this paradox is the key to understanding why this test matters.

What Lupus Anticoagulant Actually Is

LA is not a single molecule. It is a family of autoantibodies, mostly IgG and IgM types, that your immune system's B cells produce and release into your bloodstream. These antibodies target proteins that normally bind to phospholipids, the fat molecules that line cell surfaces and play a role in normal blood clotting. The two main targets are beta-2-glycoprotein I (a protein that helps regulate clotting on cell surfaces) and prothrombin (a clotting factor your liver produces).

In the lab, these antibodies compete with clotting factors for phospholipid binding sites, which slows down the clotting reaction and makes it look like your blood has trouble clotting. Inside your body, though, these same antibodies activate the cells lining your blood vessels, rev up platelets, trigger immune complement proteins, and reduce natural anticoagulant activity. The result is a system primed to form clots when it should not.

How the Test Works

LA testing is a functional coagulation assay, meaning it detects these antibodies by their behavior rather than measuring them directly. The test uses a three-step process. First, a screening test checks whether your clotting time is prolonged using reagents that are sensitive to the presence of these antibodies. The two most commonly used screening tests are the dilute Russell's viper venom time (dRVVT) and an LA-sensitive activated partial thromboplastin time (aPTT). Second, a confirmatory test adds excess phospholipid to the reaction. If the prolonged clotting time corrects when extra phospholipid is added, it proves that the antibodies were competing for phospholipid binding sites. Third, a mixing study distinguishes these antibodies from clotting factor deficiencies.

The result is reported as positive or negative, not as a number on a spectrum. There is no "low" or "borderline" lupus anticoagulant in the way you might see a borderline cholesterol result. Your blood either contains enough of these antibodies to interfere with the assay, or it does not.

Blood Clot Risk

A positive LA test is the single strongest predictor of blood clots among all antiphospholipid antibody tests. In a Hopkins Lupus Cohort study of 821 patients with systemic lupus erythematosus followed for over 75,000 person-months, LA was the best predictor of any clot, with roughly 3.5 times the risk of any blood clot, nearly 5 times the risk of venous clots (such as deep vein thrombosis or pulmonary embolism), and about 3 times the risk of arterial clots (such as stroke).

A large meta-analysis of 25 studies and over 13,000 patients confirmed this pattern: for venous blood clots, LA showed the strongest association of any antiphospholipid antibody, with about 6 times the odds of clotting. People who have had an unprovoked venous clot and test positive for LA face roughly 40% higher risk of having another clot compared to those who test negative.

Stroke and Heart Attack

The arterial risks are equally striking. In case-control studies, LA positivity was associated with more than a 40-fold increase in the odds of stroke in women under 50. In a large prospective cohort of 1,000 patients with antiphospholipid syndrome (APS) followed for 10 years, deep vein thrombosis was the most common event (39% of patients), followed by a drop in platelet count (30%), stroke (20%), pulmonary embolism (14%), and heart attack (6%).

A Swedish cohort study of 461 patients with lupus, followed for an average of about 12 years, found that patients in the cluster dominated by antiphospholipid antibodies had roughly twice the risk of major heart and vascular events and about 2.7 times the risk of venous blood clots compared to reference clusters.

Pregnancy Complications

LA is the strongest predictor of adverse pregnancy outcomes after 12 weeks of gestation. These complications include unexplained fetal death, premature birth due to preeclampsia (dangerously high blood pressure during pregnancy), and recurrent early pregnancy loss. Among women with recurrent miscarriages, approximately 10 to 15% have obstetric antiphospholipid syndrome.

Cancer Risk

A 17-year follow-up of 1,592 women with recurrent pregnancy loss found that those with positive antiphospholipid antibodies had roughly 2.5 times the risk of developing cancer compared to those without these antibodies. LA specifically was associated with about 2.6 times the risk of incident cancer. The standardized incidence ratio (the rate of cancer in this group compared to the general population) was 2.89, meaning nearly three times the expected cancer rate.

Mortality

LA positivity is linked to reduced survival. The Vienna Lupus Anticoagulant and Thrombosis Study followed 151 LA-positive patients for a median of about 8 to 9.5 years and recorded 20 deaths (13% of the cohort). New blood clots were strongly associated with death, with roughly 6 times the mortality risk even after adjusting for age and high blood pressure. Cumulative survival compared to a matched general population was 95% at 5 years and 87.7% at 10 years.

A separate 30-year Australian study of 1,854 patients with lupus found that those who developed venous blood clots had roughly twice the risk of death over the following 10 years.

Risk Stratification: Not All Positive Tests Carry the Same Risk

The combination of which antiphospholipid antibodies you carry matters enormously. Guidelines divide the risk into tiers based on your overall antibody profile.

The Vienna study further showed that conventional cardiovascular risk factors amplify the danger. By combining LA-sensitive aPTT prolongation with the presence or absence of diabetes and smoking, patients could be stratified into groups with 5-year blood clot risks of 9.7% (low), 30.9% (intermediate), and 56.8% (high).

Reference Ranges

LA testing does not produce a value you plot on a reference range chart. Instead, it generates a normalized ratio (your clotting time divided by the pooled normal clotting time). Each lab establishes its own cutoff, typically the 97.5th or 99th percentile from at least 120 healthy donors. This means exact cutoff numbers differ between labs, reagents, and testing platforms.

To give a sense of scale, one study showed that cutoff ratios for common reagent systems ranged from 1.08 to 1.17 for screening tests and 1.08 to 1.13 for confirmatory tests, even when derived from the same group of normal donors. If your result falls above the lab's cutoff, the test is reported as positive. If it falls below, it is negative.

Because the test is qualitative, you cannot compare the "strength" of one positive result to another across different labs. You can, however, track whether your result remains positive or reverts to negative over time, which is one of the most important distinctions for your clinical risk.

When Results Can Be Misleading

LA testing has one of the highest rates of misleading results of any clinical test, and the biggest culprit is anticoagulant medication. If you are taking a direct oral anticoagulant (DOAC) like rivaroxaban, apixaban, or dabigatran, your test has a 53 to 88% chance of coming back falsely positive. This does not mean you have the antibodies; it means the drug itself interferes with the phospholipid-dependent reaction the test relies on. International guidelines recommend against performing LA testing while on these medications.

Warfarin causes both false positives and false negatives by depleting clotting factors the test depends on. Heparin, both the standard intravenous form and the low-molecular-weight injectable form, can also produce false positives, though some commercial test kits include a heparin neutralizer that works at lower drug concentrations.

Acute infections and inflammation are the second most common source of false positives. During COVID-19, for example, LA positivity reached about 61% in hospitalized patients compared to 24% in controls, and this correlated with elevated CRP (a marker of inflammation). These transient positives typically resolve after the infection clears and do not indicate true antiphospholipid syndrome. This is exactly why guidelines require a second positive test at least 12 weeks later before the result is considered meaningful.

Multi-center studies show that even under controlled conditions, different laboratories disagree on whether a sample is LA-positive in 29 to 45% of cases. When patients are on warfarin, disagreement reaches 75%. For this reason, comparing results across labs is unreliable. Stick with the same lab for follow-up testing whenever possible.

Tracking Your Trend

A single positive LA test does not diagnose antiphospholipid syndrome and should not trigger major treatment decisions on its own. The 12-week confirmation rule exists because transient positivity is common. About 1% of healthy blood donors test positive for LA, but fewer than 1% of those remain positive after one year. Meanwhile, 2 to 5% of the general population carry some form of antiphospholipid antibody without ever having a clinical event.

If your first test is positive, retest at least 12 weeks later while you are free of acute illness and ideally not on anticoagulation. If both tests are positive, your risk profile is confirmed and warrants discussion about prevention strategies. If the second test is negative, the first positive was likely transient and clinically insignificant. In patients with lupus, LA can fluctuate with disease activity and corticosteroid treatment, with roughly 25% of cases toggling between positive and negative over time.

The within-person biological variation for the LA normalized ratio is about 4.6%, which is quite stable for a coagulation test. But lab-to-lab variation ranges from 5.7% to over 25% depending on the reagent system and the strength of the LA. For meaningful serial tracking, always use the same laboratory and the same testing platform.